The Losartan Market is expected to register a CAGR of 3.5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Indication (Blood Pressure, Stroke, Heart Disease); and Route of Administration (Oral). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.
Purpose of the ReportThe report Losartan Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Losartan Market Segmentation
Indication- Blood Pressure
- Stroke
- Heart Disease
- Oral
Strategic Insights
Losartan Market Growth Drivers- Increasing Prevalence of Hypertension: The Losartan market is driven by the expanding worldwide prevalence of hypertension. High blood pressure affects a substantial number of adults everywhere and leads to cardiovascular diseases as well as stroke and kidney damage. The aging global population means more people will develop hypertension which will increase the need for antihypertensive drugs such as Losartan. Healthcare professionals often prescribe Losartan because this angiotensin II receptor blocker (ARB) helps manage blood pressure through vessel relaxation which assists heart pumping. The Losartan market is set to expand as hypertension becomes more prevalent because of lifestyle elements including poor diet, insufficient physical activity and high stress levels. As more people understand the dangers of untreated high blood pressure they seek medical treatment which boosts demand for blood pressure medications such as Losartan. Healthcare providers who work to improve patient outcomes and prevent high blood pressure complications anticipate an increase in Losartan usage as a primary treatment. Doctors and patients choose Losartan because its ability to lower blood pressure and diminish heart disease risk proves highly effective. The Losartan market is projected to grow in the coming years because hypertension is becoming more common worldwide while cardiovascular health management gains importance.
- Rising Cardiovascular Disease Burden: The Losartan market continues to grow primarily because of the increasing worldwide prevalence of cardiovascular diseases (CVDs). Heart failure, coronary artery disease, and stroke are included among CVDs which stand as the top mortality causes worldwide. The growing population of people suffering from hypertension combined with diabetes, obesity and smoking habits leads to more cases of cardiovascular diseases (CVDs). Losartan serves as a vital treatment for hypertension because it reduces heart strain which is essential for protecting patients who have a high chance of heart failure and stroke. Losartan helps lower blood pressure and enhance heart function by blocking angiotensin II which constricts blood vessels to increase blood pressure and this effect reduces cardiovascular complication risks. Losartan serves as a treatment for hypertension and is prescribed to heart failure patients and those with chronic kidney disease because it protects renal function while decreasing chances of additional damage. The global increase in cardiovascular diseases especially among older adults drives up demand for effective treatment options such as Losartan. Increased awareness about early cardiovascular disease risk management advances Losartan market expansion. Healthcare providers will probably maintain their prescription practices for Losartan due to its dual advantages in blood pressure regulation and cardiovascular complication prevention which leads to continuous market growth.
- Expanding Geriatric Population: The Losartan market is expanding because the geriatric population continues to grow. The global increase in life expectancy leads to a higher number of older adults who need medical care for conditions like hypertension and cardiovascular diseases. As people age their cardiovascular systems naturally change including arterial stiffening which makes hypertension a common condition in elderly populations. The heart must work harder to pump blood when it encounters difficulty which results in higher blood pressure levels. Doctors commonly prescribe Losartan to older adults with hypertension because it helps lower their risk of heart failure along with stroke and kidney problems. Seniors usually have several concurrent health problems which necessitate complicated medical treatment plans. Older patients prefer Losartan for hypertension treatment because it demonstrates high effectiveness with minimal side effects. Losartan proves helpful for older patients who have diabetes and chronic kidney disease which frequently occur together in aged individuals. The growing elderly population in developed nations with aging populations will increase the need for Losartan. The increasing elderly population creates a major market expansion possibility for pharmaceutical companies that produce Losartan because they can now focus on this high-risk demographic to control hypertension and prevent cardiovascular diseases.
- Growing Preference for Combination Therapies: The Losartan market shows a growing trend towards combination therapies. Patients suffering from hypertension and cardiovascular diseases need multiple medications to reach ideal blood pressure control. The use of combination therapies that pair Losartan with antihypertensive agents like calcium channel blockers, diuretics or ACE inhibitors is on the rise. Combination products enhance treatment regimens by making them simpler and improving patient adherence while offering a broader approach to blood pressure management. Losartan frequently pairs with hydrochlorothiazide to increase its blood pressure-reducing capabilities. The trend emerges from increasing awareness about the advantages of combined drug treatments for complex medical conditions. Individuals who have multiple health risks like diabetes along with high cholesterol and obesity commonly need multiple medications to control their blood pressure and decrease their chances of cardiovascular issues. Patients find combination therapies more convenient since they need to take fewer pills every day which helps them adhere better to their medication regimen. As combination therapies become more popular for treating hypertension and cardiovascular diseases Losartan market growth will persist because doctors and patients are searching for treatments that combine effectiveness with convenience.
- Rising Patient Preference for Single-Dose Combination Products: Patient preference for single-dose combination medications is growing which is reshaping the Losartan market. Hypertensive patients and those with cardiovascular conditions find it difficult to follow medication schedules since they need to take multiple pills daily. Multiple health conditions require management by older adults so they frequently encounter this problem. Pharmaceutical manufacturers developed combination tablets which pair Losartan with other blood pressure medications to address this issue. Medication regimens become simpler to manage with combination products which boosts patient adherence essential to effective hypertension treatment. The medication Losartan is commonly combined with diuretics or calcium channel blockers and other angiotensin receptor blockers (ARBs) to improve blood pressure management through a unified treatment approach. Better medical results occur when patients use single-dose combination pills because they follow their medication schedule properly. The demand for Losartan combination products will rise as healthcare providers seek better hypertension management and patient adherence. Hypertension stands as the main source behind cardiovascular events and strokes and kidney damage which makes this pattern important. Single-dose combination therapies from pharmaceutical companies address both patient requirements in healthcare management and a major challenge encountered in chronic disease treatment. The Losartan combination therapies market will likely expand because individuals are learning more about the importance of following their medication schedules.
- Increasing Regulatory Support for Hypertension Treatments: The Losartan treatment market benefits from expanding regulatory support which favors hypertension therapies. Worldwide health authorities and governments now recognize the impact of hypertension on public health systems so they are focusing on improving its diagnosis and treatment. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) established fast-track approval pathways for drugs proven effective and safe against hypertension and cardiovascular conditions. Due to the regulatory framework healthcare systems can develop and introduce new treatments such as Losartan and its combination medications to market. Healthcare institutions started programs aimed at reducing hypertension incidence and improving patient outcomes through better treatment methods. The enhanced attention healthcare systems give to hypertension management will increase Losartan's use because of its proven effectiveness and regulatory backing. The Losartan market will benefit from supportive regulatory measures and medical research developments targeting hypertension treatment in the upcoming years.
- Expanding Role of Losartan in Post-Operative Care: The availability of generic Losartan presents a significant opportunity for the global market. Following major surgical procedures such as cardiovascular or renal operations patients commonly face risks including hypertension along with fluid retention and kidney damage. The medication Losartan which can dilate blood vessels to lower blood pressure is now more frequently used in post-operative treatment to handle associated risks. The renal protective properties of this medication benefit patients who undergo kidney surgeries and patients with existing kidney conditions who face potential damage during their recovery period. The increasing frequency of cardiovascular operations such as coronary artery bypass grafting (CABG) and valve replacement surgeries requires more critical attention to manage patients' blood pressure after surgery. During recovery Losartan reduces heart and circulatory system strain which leads to lowered risks of complications such as stroke or heart failure. The prevention of post-surgical hypertension and kidney complications has become the primary reason for Losartan’s adoption in hospitals and surgical centers around the world. The expected rise in Losartan use for post-operative care protocols stems from the increasing number of surgical procedures performed worldwide especially on high-risk patients. Manufacturers now have the chance to develop Losartan applications in post-operative care markets alongside its primary hypertension treatments. Companies which market Losartan for surgical recovery can advance patient health results and position themselves within a developing healthcare market area.
- Expanding Availability of Generic Losartan: The global market stands to benefit significantly from the introduction of generic Losartan. The expiration of the brand-name Losartan patents allowed generic versions to enter the market and reduce drug prices which expanded access to Losartan for more patients. The generic version of Losartan matches branded Losartan in both efficacy and safety but costs substantially less which benefits developing countries with constrained healthcare funding. Patients now have more affordable access to hypertension treatment through reduced prices which promote Losartan adoption in areas where branded medication costs are too high. The expanding market for generic drugs creates more competition between pharmaceutical companies which leads to reduced prices and better access to Losartan. Losartan manufacturers are presented with substantial market share growth potential through the expanding generic drug market in low-income nations together with middle-income countries. Generic Losartan offers effective treatment at affordable prices which helps reduce hypertension on a global scale and improves cardiovascular health results.
- Growing Adoption in Chronic Kidney Disease (CKD) Management: The Losartan market benefits from its expanding use for chronic kidney disease (CKD) management. Losartan treatment is expanding for chronic kidney disease patients because it reduces proteinuria and retards kidney damage progression especially in those with diabetic nephropathy. The worldwide rise in chronic kidney disease (CKD) cases stems from growing diabetes and hypertension prevalence which demands better kidney function management and failure prevention methods. Losartan protects kidney function and lowers renal artery pressure making it the top medication for CKD treatment alongside hypertension management. The treatment of CKD patients will drive up Losartan demand in kidney disease management. Losartan producers have a substantial chance to grow their market share in nephrology because of this trend. Losartan adoption for kidney disease management will progress because CKD continues to grow and evidence shows Losartan protects renal function.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Losartan Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Losartan Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?

Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities

Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
This text is related
to segments covered.

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Losartan Market is estimated to witness a CAGR of 3.5% from 2025 to 2031.
The major factors driving the Losartan Market are Increasing Prevalence of Hypertension, Rising Cardiovascular Disease Burden, and Expanding Geriatric Population.
Future trends in the Losartan Market are Growing Preference for Combination Therapies, Rising Patient Preference for Single-Dose Combination Products, and Increasing Regulatory Support for Hypertension Treatments.
Some of the players operating in the market are Torrent Pharmaceuticals, Macleods Pharmaceuticals, Merck, Teva Pharmaceuticals, Lupin, Cipla, Sandoz, Sun Pharmaceuticals, Unichem Laboratories, Dr. Reddy's Laboratories.
The report can be delivered in PDF/PPT format; we can also share an excel datasheet based on the request.
Some customization options available based on the request are an additional 3–5 company profiles and a country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Losartan Market - By Indication
1.3.2 Losartan Market - By Route of Administration
1.3.3 Losartan Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LOSARTAN MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LOSARTAN MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. LOSARTAN MARKET - GLOBAL MARKET ANALYSIS
6.1. LOSARTAN - GLOBAL MARKET OVERVIEW
6.2. LOSARTAN - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. LOSARTAN MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
7.1. OVERVIEW
7.2. INDICATION MARKET FORECASTS AND ANALYSIS
7.3. BLOOD PRESSURE
7.3.1. Overview
7.3.2. Blood Pressure Market Forecast and Analysis
7.4. STROKE
7.4.1. Overview
7.4.2. Stroke Market Forecast and Analysis
7.5. HEART DISEASE
7.5.1. Overview
7.5.2. Heart Disease Market Forecast and Analysis
8. LOSARTAN MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
9. LOSARTAN MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Losartan Market Overview
9.1.2 North America Losartan Market Forecasts and Analysis
9.1.3 North America Losartan Market Forecasts and Analysis - By Indication
9.1.4 North America Losartan Market Forecasts and Analysis - By Route of Administration
9.1.5 North America Losartan Market Forecasts and Analysis - By Countries
9.1.5.1 United States Losartan Market
9.1.5.1.1 United States Losartan Market by Indication
9.1.5.1.2 United States Losartan Market by Route of Administration
9.1.5.2 Canada Losartan Market
9.1.5.2.1 Canada Losartan Market by Indication
9.1.5.2.2 Canada Losartan Market by Route of Administration
9.1.5.3 Mexico Losartan Market
9.1.5.3.1 Mexico Losartan Market by Indication
9.1.5.3.2 Mexico Losartan Market by Route of Administration
9.2. EUROPE
9.2.1 Europe Losartan Market Overview
9.2.2 Europe Losartan Market Forecasts and Analysis
9.2.3 Europe Losartan Market Forecasts and Analysis - By Indication
9.2.4 Europe Losartan Market Forecasts and Analysis - By Route of Administration
9.2.5 Europe Losartan Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Losartan Market
9.2.5.1.1 Germany Losartan Market by Indication
9.2.5.1.2 Germany Losartan Market by Route of Administration
9.2.5.2 France Losartan Market
9.2.5.2.1 France Losartan Market by Indication
9.2.5.2.2 France Losartan Market by Route of Administration
9.2.5.3 Italy Losartan Market
9.2.5.3.1 Italy Losartan Market by Indication
9.2.5.3.2 Italy Losartan Market by Route of Administration
9.2.5.4 Spain Losartan Market
9.2.5.4.1 Spain Losartan Market by Indication
9.2.5.4.2 Spain Losartan Market by Route of Administration
9.2.5.5 United Kingdom Losartan Market
9.2.5.5.1 United Kingdom Losartan Market by Indication
9.2.5.5.2 United Kingdom Losartan Market by Route of Administration
9.2.5.6 Rest of Europe Losartan Market
9.2.5.6.1 Rest of Europe Losartan Market by Indication
9.2.5.6.2 Rest of Europe Losartan Market by Route of Administration
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Losartan Market Overview
9.3.2 Asia-Pacific Losartan Market Forecasts and Analysis
9.3.3 Asia-Pacific Losartan Market Forecasts and Analysis - By Indication
9.3.4 Asia-Pacific Losartan Market Forecasts and Analysis - By Route of Administration
9.3.5 Asia-Pacific Losartan Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Losartan Market
9.3.5.1.1 Australia Losartan Market by Indication
9.3.5.1.2 Australia Losartan Market by Route of Administration
9.3.5.2 China Losartan Market
9.3.5.2.1 China Losartan Market by Indication
9.3.5.2.2 China Losartan Market by Route of Administration
9.3.5.3 India Losartan Market
9.3.5.3.1 India Losartan Market by Indication
9.3.5.3.2 India Losartan Market by Route of Administration
9.3.5.4 Japan Losartan Market
9.3.5.4.1 Japan Losartan Market by Indication
9.3.5.4.2 Japan Losartan Market by Route of Administration
9.3.5.5 South Korea Losartan Market
9.3.5.5.1 South Korea Losartan Market by Indication
9.3.5.5.2 South Korea Losartan Market by Route of Administration
9.3.5.6 Rest of Asia-Pacific Losartan Market
9.3.5.6.1 Rest of Asia-Pacific Losartan Market by Indication
9.3.5.6.2 Rest of Asia-Pacific Losartan Market by Route of Administration
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Losartan Market Overview
9.4.2 Middle East and Africa Losartan Market Forecasts and Analysis
9.4.3 Middle East and Africa Losartan Market Forecasts and Analysis - By Indication
9.4.4 Middle East and Africa Losartan Market Forecasts and Analysis - By Route of Administration
9.4.5 Middle East and Africa Losartan Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Losartan Market
9.4.5.1.1 South Africa Losartan Market by Indication
9.4.5.1.2 South Africa Losartan Market by Route of Administration
9.4.5.2 Saudi Arabia Losartan Market
9.4.5.2.1 Saudi Arabia Losartan Market by Indication
9.4.5.2.2 Saudi Arabia Losartan Market by Route of Administration
9.4.5.3 U.A.E Losartan Market
9.4.5.3.1 U.A.E Losartan Market by Indication
9.4.5.3.2 U.A.E Losartan Market by Route of Administration
9.4.5.4 Rest of Middle East and Africa Losartan Market
9.4.5.4.1 Rest of Middle East and Africa Losartan Market by Indication
9.4.5.4.2 Rest of Middle East and Africa Losartan Market by Route of Administration
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Losartan Market Overview
9.5.2 South and Central America Losartan Market Forecasts and Analysis
9.5.3 South and Central America Losartan Market Forecasts and Analysis - By Indication
9.5.4 South and Central America Losartan Market Forecasts and Analysis - By Route of Administration
9.5.5 South and Central America Losartan Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Losartan Market
9.5.5.1.1 Brazil Losartan Market by Indication
9.5.5.1.2 Brazil Losartan Market by Route of Administration
9.5.5.2 Argentina Losartan Market
9.5.5.2.1 Argentina Losartan Market by Indication
9.5.5.2.2 Argentina Losartan Market by Route of Administration
9.5.5.3 Rest of South and Central America Losartan Market
9.5.5.3.1 Rest of South and Central America Losartan Market by Indication
9.5.5.3.2 Rest of South and Central America Losartan Market by Route of Administration
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. LOSARTAN MARKET, KEY COMPANY PROFILES
11.1. TORRENT PHARMACEUTICALS
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. MACLEODS PHARMACEUTICALS
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. MERCK
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. TEVA PHARMACEUTICALS
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. LUPIN
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. CIPLA
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. SANDOZ
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. SUN PHARMACEUTICALS
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. UNICHEM LABORATORIES
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. DR. REDDY'S LABORATORIES
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Torrent Pharmaceuticals
2. Macleods Pharmaceuticals
3. Merck
4. Teva Pharmaceuticals
5. Lupin
6. Cipla
7. Sandoz
8. Sun Pharmaceuticals
9. Unichem Laboratories
10. Dr. Reddy's Laboratories
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.